There are also ongoing clinical studies evaluating the effects of the VAP-1 inhibitor on reducing inflammation associated with non-alcoholic steatohepatitis (TT-01025-CL) [159]; primary sclerosing cholangitis (BTT1023, a monoclonal antibody that blocks VAP-1) [173]; and chronic kidney disease in patients with Type 2 diabetes (ASP8232) [157]. This evidence concerns the gene AOC3 and metabolic dysfunction-associated steatohepatitis.